Johnson & Johnson

Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

JOHNSON & JOHNSON TEAMS UP WITH HEALTH OFFICIALS ACROSS BRAZIL TO FIGHT ZIKA

| July 27, 2016

news image

The Olympic Games are fast approaching, and Brazil will soon host the world’s best athletes, along with thousands of fans. But the conversation dominating the headlines surrounding the Summer Games is not who will go for the gold. It’s the mosquito-borne virus known as Zika....

Read More

HOW JOHNSON & JOHNSON IS POISED TO TRANSFORM HEALTHCARE WITH 3D PRINTING TECHNOLOGIES

| July 27, 2016

news image

Dramatic changes in healthcare are happening all around us. And through these changes, companies like Johnson & Johnson have a remarkable opportunity to transform lives for the better. We have a vision for the future that is rooted in fully leveraging technology. We believe the intersection of technology and healthcare is spurring innovation that will have a profound impact on patients and consumers globally....

Read More

JANSSEN ANNOUNCES CLINICAL COLLABORATION WITH BRISTOL-MYERS SQUIBB TO EVALUATE IMMUNO-ONCOLOGY COMBINATION IN LUNG CANCER

Johnson & Johnson | July 26, 2016

news image

RARITAN, NJ – July 26, 2016 -- Janssen Biotech, Inc. announced today it has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of two immuno-oncology compounds in patients with non-small cell lung cancer (NSCLC). The Phase 2 clinical trial will evaluate the tolerability and clinical activity of the combination of Janssen’s investigational immunotherapy JNJ-64041757 and Bristol-Myer Squibb’s PD-1 immune checkpoint inhibitor, OPDIV...

Read More

U.S. FDA APPROVES PREZISTA® (DARUNAVIR) FOR USE IN PREGNANT WOMEN WITH HIV

Johnson & Johnson | July 18, 2016

news image

TITUSVILLE, NJ, July 18, 2016 – Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion to the PREZISTA® (darunavir) U.S. Prescribing Information to include data and results from a study investigating the use of PREZISTA® during pregnancy and the postpartum period....

Read More
news image

JOHNSON & JOHNSON TEAMS UP WITH HEALTH OFFICIALS ACROSS BRAZIL TO FIGHT ZIKA

| July 27, 2016

The Olympic Games are fast approaching, and Brazil will soon host the world’s best athletes, along with thousands of fans. But the conversation dominating the headlines surrounding the Summer Games is not who will go for the gold. It’s the mosquito-borne virus known as Zika....

Read More
news image

HOW JOHNSON & JOHNSON IS POISED TO TRANSFORM HEALTHCARE WITH 3D PRINTING TECHNOLOGIES

| July 27, 2016

Dramatic changes in healthcare are happening all around us. And through these changes, companies like Johnson & Johnson have a remarkable opportunity to transform lives for the better. We have a vision for the future that is rooted in fully leveraging technology. We believe the intersection of technology and healthcare is spurring innovation that will have a profound impact on patients and consumers globally....

Read More
news image

JANSSEN ANNOUNCES CLINICAL COLLABORATION WITH BRISTOL-MYERS SQUIBB TO EVALUATE IMMUNO-ONCOLOGY COMBINATION IN LUNG CANCER

Johnson & Johnson | July 26, 2016

RARITAN, NJ – July 26, 2016 -- Janssen Biotech, Inc. announced today it has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of two immuno-oncology compounds in patients with non-small cell lung cancer (NSCLC). The Phase 2 clinical trial will evaluate the tolerability and clinical activity of the combination of Janssen’s investigational immunotherapy JNJ-64041757 and Bristol-Myer Squibb’s PD-1 immune checkpoint inhibitor, OPDIV...

Read More
news image

U.S. FDA APPROVES PREZISTA® (DARUNAVIR) FOR USE IN PREGNANT WOMEN WITH HIV

Johnson & Johnson | July 18, 2016

TITUSVILLE, NJ, July 18, 2016 – Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion to the PREZISTA® (darunavir) U.S. Prescribing Information to include data and results from a study investigating the use of PREZISTA® during pregnancy and the postpartum period....

Read More